NALDEBAIN for Postoperative Pain Management in Take Down of Anastomosis

China Medical University

Status and phase: Unknown; Phase 4

Conditions: Postoperative Pain

Treatments: Drug: Morpine; Drug: Naldebain

Study type: Interventional

Funder types: Other

Identifiers

NCT03854851

CMUH107-REC2-110

Details and patient eligibility

About

NALDEBAIN ER injection, invented by Taiwanese, launched in 2017, is a nalbuphine synthetic prodrug with oil-based solution to extend the release in human body by intramuscular injection. It was approved for the premedication use for moderate to severe pain relief, expected after surgery. There was limited experience with the combination of medication and different type of surgeries. Only the effect of operative analgesia on the hemorrhoidectomy patients have been well studied. Through reviewing the past medical cases, the pain intensity after receiving take down of anastomosis was about 4 to 7 points (moderate pain), lasing about 1 to 3 days. It was a suitable population with multi-day analgesic unmet need.

At present, the standard treatment after take down of anastomosis in the CMUH was morphine as needed. This treatment might not provide for well-controlled postoperative pain management. Patients might receive more painkillers when they needed than before pain occurred. Plus, it also cost more postoperative medical care. Therefore, this study intended to compare the standard treatment and NALDEBAIN for postoperative outcomes, safety and satisfaction.

The study will enroll patients scheduled to electively undergo take down of anastomosis. Eligible subjects were randomly divided into two groups, one receiving NALDEBAIN and the other receiving standard treatment. The study will evaluate pain intensity, dosage of supplement analgesics, incidence of adverse reactions, patient satisfaction, time of the first fart after surgery, and duration of postoperative hospital stay.

Full description

This is an open-labeled, randomized clinical trial. After ICFs are signed, patients' medical history will be gained for checking if they are eligible for this study or not. And then, on Day -1, eligible ones will randomly be divide into two separate group: NALDEBAIN or MORPHINE. Group NALDEBAIN will receive Nadebain by gluteus maximus injection between 12 and 24 hours prior to surgery for postoperative pain relief. Group MORPHINE will receive morphine as needed after surgery. All necessary data will be gain form EMR or patient dairies.

Enrollment: 40 estimated patients

Sex: All

Ages: 20 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

1. Men and Women between 20 and 80 years of age
2. History of laparoscopic surgery
3. American Society of Anesthesiology Physical Class 1-3
4. Ability and willingness to provide informed consent

Exclusion criteria

1. History of hypersensitivity or allergy to opioid, NSAIDs, or Acetaminophen
2. Chronic preoperative opioid use
3. Severe comorbidity which is able to interfere pain assessment
4. Ostomy surgery of intestine within the past 8 weeks
5. Pregnant or breastfeeding

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

40 participants in 2 patient groups

NALDEBAIN

Experimental group

Description:

In group NALDEBAIN, subjects will receive single dose of Naldebain (150 mg/2 ml) by gluteus maximus injection between 12 and 24 hours prior to surgery.

Treatment:

Drug: Naldebain

MORPHINE

Active Comparator group

Description:

In group MORPHINE, subjects will receive morphine as needed after surgery.

Treatment:

Drug: Morpine